Clinical trials: High-Risk Prostate Cancer, open to volunteers
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Prostate Cancer
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external…
- Trial name
- NCT06817668
- Testing
- ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Indiana University
Prostate Cancer, Magnetic Resonance Imaging
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Population at Risk
- Trial name
- NCT05384535
- Testing
- Bi-parametric MRI
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Prostate Cancer
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer.
- Trial name
- MOB-RT (NCT05313815)
- Testing
- Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of…
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05946213
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 436 sites in United States, Canada and 3 more
- Volunteers
- 1,500 people
- Sponsor
- NRG Oncology
Prostate Cancer
Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)
BALANCE is a multicenter, prospective, randomized controlled trial enrolling men with unilateral high-risk localized prostate cancer identified by prostate biopsy, multiparametric MRI, and PSMA PET imaging.
- Trial name
- BALANCE (NCT07580196)
- Testing
- Unilateral Extended Pelvic Lymph Node Dissection, Bilateral Extended Pelvic Lymph Node Dissection
- Where
- 14 sites in Italy
- Volunteers
- 820 people
- Sponsor
- University of Turin, Italy
Prostate Cancer
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal…
- Trial name
- NCT07311915
- Testing
- Propranolol combined with novel endocrine therapy and androgen deprivation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Prostate Cancer
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Previous study findings suggest that the efficacy limitations of the neoadjuvant treatment regimen combining docetaxel with androgen deprivation therapy are associated with protein synthesis.
- Trial name
- NCT07516704
- Testing
- Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy
- Volunteers
- 94 people
- Sponsor
- Zhongda Hospital
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca
Prostatic Neoplasms
Men at High Genetic Risk for Prostate Cancer
Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated…
- Trial name
- NCT03805919
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
ExosomeDx in MRI-negative Men With High PSA
Magnetic resonance imaging (MRI) has become the current standard of care in risk stratifying men with an elevated Prostate-specific antigen (PSA) to determine who needs to undergo prostate biopsy, which is invasive and carries a…
- Trial name
- NCT06966089
- Testing
- Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy
- Where
- 6 sites in United States
- Volunteers
- 425 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Training for Men Undergoing Androgen Deprivation Therapy.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
- Trial name
- ADT-train (NCT06449664)
- Testing
- ADT-train
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- The Swedish School of Sport and Health Sciences
High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR)…
- Trial name
- NCT07875881
- Testing
- Deutenzalutamide Soft Capsules + ADT
- Where
- 3 sites in China
- Volunteers
- 1,044 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer, Recurrent Prostate Cancer
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer…
- Trial name
- NCT03495427
- Testing
- F-DCFPyL Injection, PSMA PET
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer Patients Treated by Radiotherapy
Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI
The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of…
- Trial name
- SIB-VMAT (NCT07693075)
- Testing
- Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT)
- Where
- 3 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Prostate Cancer Patients
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression.
- Trial name
- NCT03258320
- Testing
- Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Prostate Cancer, Prostatic Neoplasms
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
- Trial name
- CLARIFY (NCT06056830)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 383 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Recurrent Prostate Cancer
Partial Prostate Salvage High Dose Rate Brachytherapy
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of…
- Trial name
- SalvageHDR (NCT03246802)
- Testing
- HDR partial prostate brachytherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency